Small-molecule HDAC and Akt inhibitors suppress tumor growth and enhance immunotherapy in multiple myeloma

Small-molecule HDAC and Akt inhibitors suppress tumor growth and enhance immunotherapy in multiple myeloma

Abstract Background Multiple myeloma (MM) is an incurable disease. The acquisition of resistance to drugs, including immunomodulatory drugs (IMiDs), has a negative effect on its prognosis. Cereblon (CRBN) is a key mediator of the bioactivities of IMiDs such as lenalidomide. Moreover, genetic alterat...

Full description

Bibliographic Details
Main Authors: Mitsuhito Hirano, Yoichi Imai, Yuta Kaito, Takahiko Murayama, Kota Sato, Tadao Ishida, Junichi Yamamoto, Takumi Ito, Muneyoshi Futami, Masaki Ri, Hiroshi Yasui, Tamami Denda, Yukihisa Tanaka, Yasunori Ota, Masanori Nojima, Yasuhiko Kamikubo, Noriko Gotoh, Shinsuke Iida, Hiroshi Handa, Arinobu Tojo
Format: Article
Language:English
Published: BMC 2021-03-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
Multiple myeloma
Cereblon
Drug-resistance
HDAC inhibitor
Akt inhibitor
Dual HDAC and PI3K inhibitor
Online Access:https://doi.org/10.1186/s13046-021-01909-7

Internet

https://doi.org/10.1186/s13046-021-01909-7

Similar Items